This event is put on by OncologyEducation.
Join Erika Hamilton, MD, as she and Jan-Willem Henning MBChB, FRCPC, address a number of topics about HER2+MBC.
Topics include understanding the efficacy and safety profile of treatment options currently available for HER2+ metastatic breast cancer (HER2+ mBC), applying evidence-based guidelines on treatment algorithms and sequencing to tailor patient management strategies, and Summarizing the adverse event (AE) profile of drug therapy used in HER2+ mBC to improve awareness of AE identification, monitoring and management to optimize patient outcomes.